Core Viewpoint - Tian Tan Biological (600161) reported a revenue of 3.11 billion yuan for the first half of 2025, reflecting a year-on-year growth of 9.47%, while the net profit attributable to shareholders decreased by 12.88% to 633 million yuan [1] Financial Performance - The total operating revenue for the first half of 2025 was 3.11 billion yuan, which is an increase of 9.47% compared to the same period last year [1] - The net profit attributable to shareholders was 633 million yuan, showing a decline of 12.88% year-on-year [1] - The basic earnings per share (EPS) stood at 0.32 yuan [1] Factors Influencing Performance - The decline in net profit was attributed to several factors, including a decrease in product sales prices compared to the previous year and changes in credit policies that led to reduced interest income [1]